TABLE 1.
METTL14 acts as anti‐oncogene and oncogene in human cancers
| Role | Cancer type | Regulator | Targets | Molecular mechanism | Signaling pathway/Axis | Ref. |
|---|---|---|---|---|---|---|
| Anti‐oncogene | Bladder cancer | Notch1 | mRNA stabilization | METTL14 ‐ m6A modification ‐ Notch1 axis | 55 | |
| Colorectal cancer | SOX4 | mRNA degradation | METTL14 ‐ YTHDF2 ‐ SOX4 axis; SOX4‐mediated EMT process and PI3K/AKT signaling pathway partly | 56 | ||
| DGCR8 | miR‐375 | Modulate pri‐miR‐375 process in an m6A‐dependent manner | METTL14 ‐ miR‐375 ‐ YAP1 axis and METTL14 ‐ miR‐375 ‐ SP1 axis | 57 | ||
| lncRNA XIST | LncRNA degradation | METTL14 ‐ YTHDF2 ‐ lncRNA XIST axis | 58 | |||
| MeCP2 | KLF4 | mRNA stabilization | MeCP2 ‐ METTL14 ‐ KLF4 axis | 75 | ||
| Endometrial cancer | PHLPP2; mTORC2 | Promote translation by YTHDF1; mRNA degradation by YTHDF2 | METTL14‐ PHLPP2/mTORC2‐AKT pathway | 60 | ||
| Gastric cancer | Wnt and PI3K signals | Regulate Wnt and PI3K/AKT/mTOR pathway | Wnt and PI3K/AKT/mTOR signaling pathways | 61, 79 | ||
| LINC01320 | LncRNA stabilization | METTL14 ‐ LINC01320 ‐ miR‐495‐5p ‐ RAB19 axis | 62 | |||
| PTEN | mRNA stabilization | METTL14 ‐ m6A modification ‐ PTEN axis | 80 | |||
| Glioblastoma | ADAM19 | mRNA m6A modification | METTL14 ‐ m6A modification ‐ ADAM19 axis | 63 | ||
| Hepatocellular carcinoma | DGCR8 | miR‐126 | Modulate pri‐miR‐126 process in an m6A‐dependent manner | DGCR8 ‐ METTL14 – miR‐126 axis | 64 | |
| USP48 | mRNA stabilization | METTL14 ‐ USP48 ‐ SIRT6 axis | 65 | |||
| EGFR | Stimulate PI3K/AKT signals | EGFR/PI3K/AKT signaling pathway | 66 | |||
| Renal cell carcinoma | P2RX6 | pre‐mRNA splicing | ATP‐P2RX6‐Ca2+‐p‐ERK1/2 ‐MMP9 signals | 68 | ||
| circRNAs | PTEN | mRNA stabilization | circRNAs ‐ miRNAs ‐ METTL14 ‐ PTEN axis | 52 | ||
| Papillary thyroid carcinoma | OIP5‐AS1 | Regulate expression | EGFR, MEK/ERK signaling pathway | 86 | ||
| Osteosarcoma | Caspase‐3 | Activate caspase‐3 | Apoptosis | 87 | ||
| Skin tumor | NBR1‐dependent autophagy | DDB2 | Translation efficiency | NBR1‐dependent autophagy ‐ METTL14 – DDB2 axis | 53 | |
| Oncogene | Acute myeloid leukemia | SPI1 | MYB; MYC | Accelerate hematopoietic stem cells proliferation and reduce monocyte differentiation | SPI1 ‐ METTL14 ‐ MYB/MYC axis | 46 |
| MALAT1 | PML‐PARα | mRNA exportation | lncRNA ‐ fusion gene ‐ METTL14 loop | 92 | ||
| Breast cancer | LNC942 | CXCR4; CYP1B1 | mRNA stabilization and translation | LNC942 ‐ METTL14 ‐ CXCR4/CYP1B1 axis | 49 | |
| AURKA | DROSHA | mRNA stabilization | AURKA ‐ METTL14 ‐ DROSHA axis | 47 | ||
| Pancreatic cancer | PERP | mRNA turnover | METTL14 ‐ m6A modification ‐ PERP axis | 95 | ||
| P65 | CDA | mRNA stabilization | P65 ‐ METTL14 ‐ CDA axis | 48 | ||
| Prostate cancer | CLK1‐SRSF5 axis | Alternative splicing | CLK1 ‐ SRSF5 ‐ METTL14exon10 skipping axis | 97 | ||
| Head and neck squamous cell carcinoma | LNCAROD | LncRNA stabilization | METTL14 – LNCAROD ‐YBX1/HSPA1A axis | 99 | ||
| EBV‐related tumors | EBNA3C | Maintain METTL14 protein stability | 54 |